PRNewswire (Thu, 9-Jul 7:57 PM ET)
Globe Newswire (Wed, 8-Jul 9:34 AM ET)
Market Chameleon (Fri, 26-Jun 4:36 AM ET)
Business Wire (Fri, 26-Jun 8:30 AM ET)
Omeros Announces Webcast Details for Annual Meeting of Shareholders
Business Wire (Mon, 15-Jun 8:30 AM ET)
Omeros Delivers First Profitable Quarter as YARTEMLEA Launch Transforms Financial Trajectory
Market Chameleon (Thu, 14-May 6:17 AM ET)
Omeros Corporation Reports First Quarter 2026 Financial Results
Business Wire (Wed, 13-May 4:02 PM ET)
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
Business Wire (Mon, 11-May 4:02 PM ET)
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
Globe Newswire (Mon, 20-Apr 7:00 AM ET)
Market Chameleon (Thu, 16-Apr 5:24 AM ET)
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Omeros trades on the NASDAQ stock market under the symbol OMER.
As of July 16, 2026, OMER stock price declined to $9.22 with 2,165,705 million shares trading.
OMER has a beta of 3.13, meaning it tends to be more sensitive to market movements. OMER has a correlation of 0.13 to the broad based SPY ETF.
OMER has a market cap of $667.30 million. This is considered a Small Cap stock.
Last quarter Omeros reported $10 million in Revenue and -$.24 earnings per share. This fell short of revenue expectation by $-157,000 and exceeded earnings estimates by $.06.
In the last 3 years, OMER traded as high as $17.65 and as low as $.92.
The top ETF exchange traded funds that OMER belongs to (by Net Assets): VTI, IWM, VXF, XPH, PBE.
OMER has outperformed the market in the last year with a return of +155.4%, while the SPY ETF gained +21.9%. However, in the most recent history, OMER shares have underperformed the stock market with its stock returning -24.7% in the last 3 month period and -2.0% for the last 2 week period, while SPY has returned +7.5% and +0.7%, respectively.
OMER support price is $9.81 and resistance is $10.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OMER shares will trade within this expected range on the day.
